Brokerages Expect Infinity Pharmaceuticals Inc. (INFI) Will Announce Earnings of -$0.17 Per Share

Equities research analysts forecast that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post earnings per share (EPS) of ($0.17) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Infinity Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.16). Infinity Pharmaceuticals posted earnings per share of ($0.14) in the same quarter last year, which indicates a negative year-over-year growth rate of 21.4%. The company is scheduled to report its next quarterly earnings results on Thursday, March 21st.

On average, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.23) per share for the current fiscal year, with EPS estimates ranging from ($0.25) to ($0.22). For the next financial year, analysts forecast that the business will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.79) to ($0.70). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Monday, November 5th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.37. The firm had revenue of $22.00 million for the quarter.

Several equities research analysts have recently issued reports on INFI shares. Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Tuesday, September 25th. JPMorgan Chase & Co. lowered shares of Infinity Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Monday, November 12th. Finally, Wells Fargo & Co lowered shares of Infinity Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, November 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $3.50.

In related news, major shareholder Value Fund L. P. Biotechnology purchased 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 28th. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $130,000.00. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Bvf Partners L. P/Il purchased 91,474 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The shares were bought at an average price of $1.35 per share, for a total transaction of $123,489.90. The disclosure for this purchase can be found here. Insiders have purchased a total of 3,730,634 shares of company stock worth $5,090,055 over the last quarter. 11.45% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the stock. Algert Global LLC acquired a new stake in Infinity Pharmaceuticals during the 2nd quarter worth $139,000. Acadian Asset Management LLC raised its stake in Infinity Pharmaceuticals by 95.2% during the 2nd quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 181,436 shares in the last quarter. Opaleye Management Inc. acquired a new stake in Infinity Pharmaceuticals during the 3rd quarter worth $745,000. Fosun International Ltd acquired a new stake in Infinity Pharmaceuticals during the 3rd quarter worth $879,000. Finally, Essex Investment Management Co. LLC raised its stake in Infinity Pharmaceuticals by 121.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock worth $988,000 after acquiring an additional 199,796 shares in the last quarter. Hedge funds and other institutional investors own 52.16% of the company’s stock.

Shares of Infinity Pharmaceuticals stock traded up $0.05 during trading on Friday, hitting $1.29. 289,000 shares of the stock were exchanged, compared to its average volume of 591,134. The stock has a market cap of $68.81 million, a P/E ratio of -1.55 and a beta of 2.51. Infinity Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $2.92.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

See Also: Price to Earnings Ratio (PE), For Valuing Stocks

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply